Thank you very much, and thanks for dialing in to this quarterly financial call. I have our CFO, Monica Johnson, with me, and we are pleased to present our results and answer any questions you may have subsequent to the presentation.
So we just released the first quarterly report, and it was a soft quarter due to lower sales in EMEA; the quarter resulted in net sales that decreased by 14.6% to a revenue of 166 million. So that's an organic decrease of 6.6%, as we had almost 8% headwind on currency; EBITDA amounted to 40 million.
So that corresponds to 24%.
As we say in the report, EMEA is affected by inventory adjustment.
With our main distribution partner. And that is what has caused this significant negative growth compared to the comparable quarter last year.
So that's the bad news. There are no fundamental changes to our business model or the market conditions. But this is the situation that we announced today.
We are also announcing that we have continued momentum in our strong region in Americas, and we continue to see double-digit organic growth in Americas. And furthermore, this is getting broader within APAC, we see traction to convert labs and we see positive development coming out here in Q1 with regards to our strategic direction. Since we've been investing in new product development for quite some years, and now we are starting to launch these new components. And there are good examples coming out here in Q1. We have launched the CellaVision® Bone Marrow Aspirate (BMA) Application. After we received the CE mark, which was planned for Q1, but we obtained it just before Christmas 2025.
So we have started our sales campaigns. We've started participating at conferences and we're in the process of training our distribution partners Sysmex to really position this, I would say, great product to the clinical community. So we expect to see a funnel being built throughout 2026 and that will result in revenues contributing in the second half of this year.
We've also launched globally our updated software. This is the largest software upgrade for our platform ever. So it contains both user interface and improved workflow and features. And also, for the new Di 60, higher turnaround. So more blood samples can be processed. So it's a very, very powerful package that is now available both to upgrade existing instruments and networks, but also as part of the new Di 60 systems.
And then finally, in our investment program, it is important to emphasize that we are still extremely confident and we're pushing our next generation solutions with FPM, both for hematology. And then we're exploring our opportunities very successfully to also be deployed in other areas such as cytology and pathology.
So let's unpack the P&L.
So Net sales were 166 million, excuse me, representing -15% growth or -6.6% organic growth up against last year. We had a gross margin of 68%. And that entails also an increase in our amortization of capitalized development expenditures, given the bone marrow and the upgraded software program that I just talked about. So, here we are now depreciating 3 million versus 2 million. Operating expenses landed at 51% versus 41%.
In fact, it's equivalent to a higher spend of operating expenses of 5 million. And that 5 million is actually also the difference in what we are capitalizing.
So EBITDA was 40 million, representing 24%, which is, of course, lower than our expectations and a function of the miss in the top line that I will explain a little bit later.
We are still investing in our R&D, but there are also changes to the maturity or early stage of the programs we are running, which is also a function of how much we can capitalize. So that's also part of the reason why you see a different capitalization of 12 million this quarter versus in the comparable quarter, 18 million.
So, we had significant hardware investments in the comparable quarter that are not reflected in this quarter. So that's a function of the program.
Finally, regarding operating cash flow.
62 million. We had 40 million, then plus the working capital. We had accounts receivable that contributed positively to our operating cash flow of 62. And then we had investments and financing activities that are deducted. And that results in a total cash flow of 42 million. Still, as always, a positive cash flow. And now with cash and cash equivalents, the company has 230 million sitting on the balance sheet.
So the regional highlights. In America, it is really important for me, the team, and our partner to emphasize the strong momentum we have with 13% organic growth. So 2%, but a negative currency effect of 12 leads to 13% growth. And we saw continued strong adoption of our integrated large instruments for the hospital community around the US, we are focusing and pushing the concept of connected labs to position the DC one in these integrated health networks.
So we are working very strongly together with our American partner organization.
To push this, we also saw a little bit regarding the small lab segment that is served by the instrument. Regarding the DC one, we actually observed a slight instrument decline, which also followed a period of pent-up purchases of small instruments. Given the tariffs and uncertainties throughout 2025, there's a lot of activities going on to really serve this segment. And there's a lot of appetite for that value proposition of connecting that with our integrated solution for these networks.
And yes, we mentioned some market uncertainties. I'd say demand-wise, there is still really a need, an ongoing appetite to digitalize the labs across the different markets that are immature and mature in very different degrees. So what we hear is that public funding is a little bit under pressure, given the defense situation of Europe, which does delay certain tender specs. So that's kind of the market condition, but the -32% growth or -26% organic growth is not related to the market.
This is really a situation around the temporary reduction in excessive inventory that hit us in this Q1.
So the root cause here is a number of excess units sitting in multiple affiliates. Probably over some time, that has happened to mitigate delivery risk from ERP implementations. As our partner Sysmex's fiscal year ends by the end of March, there's been a strong push to cut down and really examine where they have inventories. And that has resulted in obviously fewer orders, significantly fewer orders for us in this quarter. And that is really what we're reporting here.
It's important for us to emphasize that we flagged this. Is it over? Is all inventory complete in Q1? We cannot promise that some inventory will not persist into the second quarter. So stock may still remain in Q2. However, we expect better instrument sales in Q2, and we don't expect negative growth, but it's a little bit too early to say what growth will come in Q2.
So we're being extremely transparent and conservative here, but I think it is really the best of our current knowledge.
However, as I said, it's early days with one month into Q2, and for APAC, we landed at 10% growth.
So 22 million, of course, is up against smaller numbers, so to speak. Having said that, the positive thing is that we start to see traction across APAC.
We have previously been very exposed in China, and we are seeing diversification and a broader demand for our solutions across Southeast Asia, which is super positive.
We'll take the numbers, which on this slide are presented by product category. For instruments, the highlighted miss amounted to 86 million compared to 115 million in the comparable quarter, essentially representing the EMEA miss we are seeing; for the stable reagent business, what we have managed to do over the years, with APAC previously being insignificant, is now getting to a level where it starts to really contribute.
It's across multiple countries as we have launched our classic stain portfolio across APAC together with Sysmex. And here this quarter, we reached almost 4 million versus a comparable figure of 1.4 million.
So we are starting to see some traction here, which is truly a signal of a long journey and extremely positive, even though software and others saw a -2% change.
So pretty much flat.
I would say though, that the software is less than it was in the comparable quarter. And that is a function of less instruments. And then there's a little bit more on others, which entails spare parts and also our FX.
So, on this final slide, our key takeaways.
Yes, we are extremely transparent around our soft quarter, which is really due to the lower sales in EMEA. And this is the root cause for having only -7% organic growth, which is of course, not in line with our expectations. However, we still think that there are opportunities across EMEA. And that is also the signal we get from our partner that there are multiple opportunities across the different segments we operate in for Americas.
Strong momentum. It continues. And also here, I would say there are opportunities with new products.
And that leads me into the bone marrow.
And other news that we report is that we have filed to the FDA our bone marrow application.
So we're in process of registering our bone marrow application as a 510(k) and get clearance for that for the US so we can start commercializing the bone marrow application together with the DI-60 and our remote review software as a package to support the clinicians who are diagnosing. leukemias, lymphomas from bone marrow.
And then again, I mentioned our software upgrade. There are multiple global training activities going on across the Sysmex organization to position our software 72, which allows the hospitals to get improved user interface and a better workflow, more speed if they go with the new Di 60. So that's really another pivotal thing.
And then, as also mentioned in the beginning, we are extremely confident but also extremely committed development-wise to continue to push our relatively mature development program for our next-generation solution that entails our new microscopy technology under the name of FPM Fourier Ptychographic Microscopy, and are also exploring and seeing opportunities in adjacent segments such as cytology and pathology.
So with that, I think I will close the presentation, and then Monica and myself would be happy to take any questions you may have.
Thank you.